中华内分泌代谢杂志
中華內分泌代謝雜誌
중화내분비대사잡지
CHINESE JOURNAL OF ENDOCRINOLOGY AND METABOLISM
2015年
3期
224-229
,共6页
李秀敏%吴黄辉%肖远%王晓明
李秀敏%吳黃輝%肖遠%王曉明
리수민%오황휘%초원%왕효명
绿茶提取物%代谢综合征%脂质代谢%Meta分析%随机对照研究
綠茶提取物%代謝綜閤徵%脂質代謝%Meta分析%隨機對照研究
록다제취물%대사종합정%지질대사%Meta분석%수궤대조연구
Green tea extract%Metabolic syndrome%Lipid metabolism%Meta-analysis%Randomized controlled trial
目的 系统评价绿茶提取物改善代谢综合征患者脂质代谢的疗效和安全性.方法 计算机检索中英文文献,收集绿茶提取物与代谢综合征患者脂质代谢相关的随机对照试验,采用RevMan 5.2软件进行meta分析.结果 纳入9篇随机对照研究文献,共566例代谢综合征患者.Meta分析结果显示,与安慰剂组相比,在治疗终点时绿茶提取物有效降低代谢综合征患者低密度脂蛋白胆固醇(LDL-C)水平[SMD=-0.33,95％ CI(-0.56,-0.09),P=0.007],差异有统计学意义,高密度脂蛋白胆固醇[SMD=0.19,95％ CI(-0.04,0.43),P=0.10]、总胆固醇[SMD=-0.13,95％ CI(-0.39,0.13),P=0.33]及甘油三酯[SMD=-0.07,95％ CI(-0.46,0.33),P=0.74]水平2组差异无统计学意义.绿茶提取物组和安慰剂组总体不良反应发生率差异无统计学意义[OR=0.97,95％ CI(0.54,1.76),P=0.93].结论 绿茶提取物可有效降低代谢综合征患者LDL-C水平,且不良反应少.
目的 繫統評價綠茶提取物改善代謝綜閤徵患者脂質代謝的療效和安全性.方法 計算機檢索中英文文獻,收集綠茶提取物與代謝綜閤徵患者脂質代謝相關的隨機對照試驗,採用RevMan 5.2軟件進行meta分析.結果 納入9篇隨機對照研究文獻,共566例代謝綜閤徵患者.Meta分析結果顯示,與安慰劑組相比,在治療終點時綠茶提取物有效降低代謝綜閤徵患者低密度脂蛋白膽固醇(LDL-C)水平[SMD=-0.33,95％ CI(-0.56,-0.09),P=0.007],差異有統計學意義,高密度脂蛋白膽固醇[SMD=0.19,95％ CI(-0.04,0.43),P=0.10]、總膽固醇[SMD=-0.13,95％ CI(-0.39,0.13),P=0.33]及甘油三酯[SMD=-0.07,95％ CI(-0.46,0.33),P=0.74]水平2組差異無統計學意義.綠茶提取物組和安慰劑組總體不良反應髮生率差異無統計學意義[OR=0.97,95％ CI(0.54,1.76),P=0.93].結論 綠茶提取物可有效降低代謝綜閤徵患者LDL-C水平,且不良反應少.
목적 계통평개록다제취물개선대사종합정환자지질대사적료효화안전성.방법 계산궤검색중영문문헌,수집록다제취물여대사종합정환자지질대사상관적수궤대조시험,채용RevMan 5.2연건진행meta분석.결과 납입9편수궤대조연구문헌,공566례대사종합정환자.Meta분석결과현시,여안위제조상비,재치료종점시록다제취물유효강저대사종합정환자저밀도지단백담고순(LDL-C)수평[SMD=-0.33,95％ CI(-0.56,-0.09),P=0.007],차이유통계학의의,고밀도지단백담고순[SMD=0.19,95％ CI(-0.04,0.43),P=0.10]、총담고순[SMD=-0.13,95％ CI(-0.39,0.13),P=0.33]급감유삼지[SMD=-0.07,95％ CI(-0.46,0.33),P=0.74]수평2조차이무통계학의의.록다제취물조화안위제조총체불량반응발생솔차이무통계학의의[OR=0.97,95％ CI(0.54,1.76),P=0.93].결론 록다제취물가유효강저대사종합정환자LDL-C수평,차불량반응소.
Objective To systematically evaluate the efficacy and safety of green tea extract (GTE) in improving lipid metabolism in patients with metabolic syndrome (MS).Methods All relevant published articles in Chinese and English literature database were searched to collect the randomized controlled trials comparing the efficiency and safety of GTE in patients with MS.The meta-analysis was performed using RevMan 5.2 software.Results Nine studies involving 566 patients were included.The results of recta-analysis showed that:GTE significantly reduced the level of low-density lipoprotein cholesterol (LDL-C) (SMD =-0.33,95％ CI-0.56 ～ -0.09,P=0.007)compared with placebo at the treatment endpoint.There were no statistical significance in high-density lipoprotein cholesterol (SMD =0.19,95 ％ CI-0.04 ～ 0.43,P =0.10),total cholesterol (SMD =-0.13,95％ CI-0.39 ～ 0.13,P =0.33),and triglyceride (SMD =-0.07,95％ CI-0.46 ～ 0.33,P =0.74) levels between two groups.There was no significant difference in the overall rate of adverse events between two groups (OR =0.97,95 ％ CI 0.54 ～ 1.76,P =0.93).Conclusion GTE significantly reduces the level of LDL-C in patients with MS,and the adverse events were rare and mild.
